Lab ripening of eggs for women with infertility, called CAPA IVM
Tests CAPA IVM, an egg maturation method, in women with infertility.
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- CAPA In-vitro Oocyte Maturation
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 10 Nov 2025
- Expected to end
- 31 May 2032
- Type of study
- Interventional
- Treatments tested
- CAPA IVM
- Record updated
- 8 December 2025
Who can take part
The trial is looking for girls and women who want fertility preservation or egg collection. Eggs are matured outside the body (CAPA-IVM).
- Age
- 0 months to 50 years
- Sex
- Female only
- Main reasons for not taking part
- People who cannot give consent or assent, for example because of serious psychiatric problems or cognitive delay
Show the full registry criteria (4)Hide the full registry criteria
Who can take part
- Patients aged from 0-50 years old
- Patients seek fertility preservation services
- Patients seek oocyte retrieval services
Who cannot take part
- -Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Female infertility
This trial is currently available in Hong Kong.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.
The group in the trial
- CAPA-IVMTreatment being tested
In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- CAPA In-vitro Oocyte Maturation
- Plain-language title
- Lab ripening of eggs for women with infertility, called CAPA IVMGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06984081, who can take part
- Record updated
- 8 December 2025